Federal Register / Vol. 65, No. 25 / Monday, February 7, 2000 / Notices 5879

received by the NIH Office of

Technology Transfer on or before April

7, 2000, will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Charles Maynard,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 243; Facsimile: (301) 402–

0220; e-mail: CM251N@NIH.GOV.

SUPPLEMENTARY INFORMATION: This

invention relates generally to modified

glycoprotein hormones and specifically

to modifications to a human

glycoprotein, which create superagonist

activity. Glycoprotein hormones

comprise a family of hormones, which

are structurally related heterodimers

consisting of a species common α subunit and a distinct β sub-unit that

confers the biological activity for each

hormone. However, this invention is not

limited to specific hormones, specific

subjects such as humans as well as nonhumans mammals, specific amino acids,

specific clinical conditions, specific

analogs, or specific methods.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: February 1, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–2630 Filed 2–4–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Nitroxides as Protectors

Against Oxidative Stress and in the

Prophylactic and Therapeutic

Treatment of Aging, Obesity and

Cancer

AGENCY: National Institutes of Health,

Public Health Service, DHHS

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 07/494,532, filed

March 16, 1990, entitled ‘‘Nitroxide as

Protectors Against Oxidative Stress’’

and U.S. Patent Application Serial No.

60/047,724 filed May 27, 1997 entitled,‘‘

The use of Nitroxides in the

prophylactic and therapeutic treatment

of cancer due to genetic defects’’ and

corresponding foreign patent

applications to Mitos, Inc., having a

place of business in San Diego,

California. The patent rights in these

inventions have been assigned to the

United States of America.

The contemplated exclusive license

may be limited to the use compounds

and methods disclosed and claimed in

the invention for the prevention and

treatment of obesity, cancer and the

amelioration of the direct effects of

aging.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before May 8,

2000, will be considered.

ADDRESSES: Requests for a copy of the

patent application, inquires, comments

and other materials relating to the

contemplated license should be directed

to: Norbert J. Pontzer, J.D., Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7736, ext. 284; Facsimile: (301) 402–

0220; E–mail: np59n@nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent application.

SUPPLEMENTARY INFORMATION: New

metal-independent nitroxide

compounds are anti-oxidants capable of

protecting cells, tissues, and organs

against the harmful effects of toxic

oxygen related species (hydroxyl

radical, hydrogen peroxide, superoxide).

The toxic oxygen related species have

been implicated in cancer and aging.

These nitroxides slow the death rate in

experimental animals with cancers

caused by deletion of the p53

suppressor gene. These nitroxides also

cause weight loss in mice with no

apparent toxicity.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 90 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 31, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–2631 Filed 2–4–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Nitroxides as Protectors

Against Oxidative Stress and the

Prophylactic and Therapeutic

Treatment Radiation Damage to

Normal Tissue

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 07/494,532, filed

March 16, 1990, entitled ‘‘Nitroxides as

Protectors Against Oxidative Stress’’

and U.S. Patent Application Serial No.

60/047,724 filed May 27, 1997 entitled,